FDA INFORMED CONSENT WAIVER RULE EXPANSION TO PERMANENT DISABILITY STUDIES SOUGHT BY RESEARCHERS; NEED FOR SEPARATE IDEs FOR ALL PRODUCTS QUESTIONED
This article was originally published in The Gray Sheet
Executive Summary
FDA's informed consent waiver rule should be expanded to allow emergency research in situations likely to result in serious and permanent disability, the Coalition of Acute Resuscitation and Critical Care Researchers argues in Oct. 17 comments submitted to the agency.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.